Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia
- 1 May 2006
- journal article
- letter
- Published by Elsevier in Experimental Hematology
- Vol. 34 (5) , 571-572
- https://doi.org/10.1016/j.exphem.2006.02.009
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpuraAmerican Journal of Hematology, 2005
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot studyEuropean Journal of Haematology, 2002